Sunday 8 November 2026 · Edition of the day

Current editionPast editions →

The Skeptic's Daily

The day's biggest stories, taken apart. For each one: what is actually established, what is only asserted, the questions worth asking — and a plausibility score for the central claim, given everything currently known.

Stories
1
Average plausibility
84%
How to read the score
It rates how well the core claim is evidenced — not how important the story is, nor whether it is good or bad news.
01HealthGlobal

Ebola research highlights vaccine gap for Bundibugyo strain

Recent reports support the lack of a licensed Bundibugyo vaccine, but promising research has not yet established protection against the virus.

DW reports that Bundibugyo Ebola is causing a current outbreak and that new research raises hopes for broader vaccine protection. A recent MSF brief places the outbreak response in the Democratic Republic of the Congo and says no vaccine is licensed specifically for Bundibugyo. MSF says researchers are testing existing Ebola vaccines and new candidates, but protection from Ervebo against Bundibugyo remains unproven.

What holds up

  • ✓DW and MSF both describe a current Bundibugyo outbreak. MSF's recent brief also supports the central vaccine gap, with the more precise wording that no vaccine is licensed specifically for Bundibugyo.
  • ✓Research is underway, rather than merely proposed: MSF names the BRAVO study and Tumaini trial. As background, a July ANRS account reports that samples from people vaccinated against Zaire Ebola contained antibodies against Bundibugyo, while explicitly warning that this does not demonstrate clinical protection.

What doesn't yet

  • ?DW's wording that there is “no vaccine” is too broad without qualification. Candidates exist, and MSF says the DRC is using Ervebo, but its effectiveness against Bundibugyo remains unproven.
  • ?The supplied DW excerpt does not identify the research behind its optimism or provide methods or results. The older antibody findings offer a reason to investigate, not evidence that a vaccine protects people against several Ebola types.
  • ?Only a few outside newsrooms are represented in the evidence used here, so other accounts may be missing. ReliefWeb repeats the MSF brief rather than providing a separate reporting check; MSF also leads one of the studies. These excerpts are not full-article verification.

Ask before you share

  • →Which study does DW mean, and did it measure antibodies, illness prevention, or another outcome?
  • →Have trials shown that Ervebo or a Bundibugyo-specific candidate prevents disease, and what safety and effectiveness results are available?
  • →Does “no vaccine” mean no licensed Bundibugyo vaccine, rather than no experimental options or vaccines being tested for protection?

Sources & original reporting

  1. [1]DW · Published 7 Nov 2026 · dw.com
  2. [2]Reliefweb · Published 2 Nov 2026 · reliefweb.int
  3. [3]Msfaccess · Published 27 Oct 2026 · msfaccess.org
  4. [4]Anrs · Published 24 Jul 2026 · anrs.fr